Viral hepatitis: testing saves lives
Every year, around 50 000 newly diagnosed cases of hepatitis B and C are reported across Europe but millions are unaware of their infection. Left untreated, hepatitis can cause irreversible liver damage. Hepatitis A is recognised as a re-emerging health threat in Europe.
Investing in HIV response essential to curb on-going HIV transmission in Europe.Archived
New data for 2011 show that more than 121 000 new HIV cases were reported in the WHO European Region, including more than 28 000 new infections in the European Union and the European Economic Area (EU/EEA), indicating an increase for the whole Region compared to the previous year1.
ECDC Vaccine Scheduler
The Vaccine Scheduler is an interactive tool that shows vaccination schedules for individual EU/EEA countries and specific age groups. With this tool comparisons can be made for vaccination schedules between two countries or by disease for all or a selection of countries.
- Hepatitis A
- Hepatitis B
- Human papillomavirus infection
- Influenza in humans, seasonal
- Invasive Haemophilus influenzae disease
- Meningococcal disease
- Pneumococcal disease
- Prevention and control
- Rotavirus infection
- Tick-borne diseases
Response plan to control and manage the threat of multidrug-resistant gonorrhoea in Europe
This response plan is designed to prevent the spread of multidrug-resistant Neisseria gonorrhoeae (MDR NG) in the EU/EEA in the context of the possible emergence of untreatable gonorrhoea
Review of Chlamydia Control Activities in EU Countries
This report illustrates the scope and the findings of Project SCREen, arguably the biggest study to date on chlamydia control activities in the EU. In addition to data from EU Member States, SCREen also collected data from EU candidate countries, EFTA member states, and the USA.
Novel approaches to testing for sexually transmitted infections, including HIV and hepatitis B and C in Europe
This report focuses on novel approaches to testing for sexually transmitted infections, human immunodeficiency virus, hepatitis B virus and hepatitis C virus that are relevant for the prevention and control of these infections at EU/EEA level.